Association of Lipoprotein(a) With Postoperative Atrial Fibrillation

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAnthony Tang

About this trial

About one in three patients who undergo open-heart surgery develop an irregular heart rhythm called postoperative atrial fibrillation (POAF). This condition increases the risk of stroke, prolongs hospital stays, and raises the chances of complications and death compared with patients who do not develop it. Because of these serious outcomes, researchers are working to identify which patients are most at risk.

One potential blood marker is lipoprotein(a), or Lp(a). Higher levels of Lp(a) have been linked to abnormal heart rhythms in previous studies. We want to determine whether patients with elevated Lp(a) are more likely to develop POAF after heart surgery and better understand the biological mechanisms behind this risk.

In this study, patients will be grouped based on whether they have high or low Lp(a) levels. All participants will wear a chest band monitor that continuously tracks heart rhythm for 3 months after surgery to detect POAF. During surgery, small tissue samples from the heart will also be collected. By examining these samples, we will assess whether patients with elevated Lp(a) show more scarring and inflammation which are two pathways known to cause abnormal heart rhythms.

The goal of this study is to determine whether elevated Lp(a) increases susceptibility to POAF. This could help identify patients who may benefit from preventive treatments and closer monitoring. By understanding how Lp(a) affects heart tissue, we also hope to uncover the mechanisms that contribute to abnormal rhythm and guide the development of future targeted therapies to treat POAF and other heart rhythms.

Eligibility criteria

Qualifiers

Age ≥18 years

Scheduled for elective or urgent CABG, valve replacement, or combined CABG and valve replacement

Willing to wear the Skiin chest band for the duration of the study

Have a smartphone with an Operating System compatible with the

Disqualifiers

Emergency indication for CABG, valve replacement, or combined CABG and valve replacement

Prior cardiac surgery

History of pre-operative persistent atrial fibrillation

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

20 Participants
are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators

Anthony Tang

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Sponsor institution